Efficacy and Safety of Nipocalimab in Adults With Generalised Myasthenia Gravis: An Asian Subgroup Analysis of the Vivacity-MG3 Study
Open Access
- 1 January 2026
- journal article
- Published by XMLink in Journal of Clinical Neurology
- Vol. 22 (4) , 446-455
Abstract
Nagane Y, et al. J Clin Neurol. 2026 ;22:e42. https://doi.org/10.3988/jcn.2025.0290Keywords
Funding Information
- Johnson & Johnson Innovative Medicine Asia Pacific
This publication has 15 references indexed in Scilit:
- Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled studyThe Lancet Neurology, 2025
- Myasthenia gravis: the future is hereJournal of Clinical Investigation, 2024
- Myasthenia gravis: the changing treatment landscape in the era of molecular therapiesNature Reviews Neurology, 2024
- Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Neurology, 2023
- The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndromeClinical and Experimental Neuroimmunology, 2023
- Neonatal Fc Receptor–Targeted Therapies in NeurologyNeurotherapeutics, 2022
- Placebo effect in the management of chronic painBJA Education, 2020
- Myasthenia gravisNature Reviews Disease Primers, 2019
- M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human StudyClinical Pharmacology & Therapeutics, 2018
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyThe Lancet Neurology, 2017